

Ref. No: 183150520
From: Public
Date: 15/05/2020
Subject: Pharmaceutical Records

REQUEST

Hi,

I have a Freedom of Information request that I hope you'll be able to help me with
Could you please provide me with the following numbers of patients treated in the last 3 months with the following drugs, regardless of disease.

Abatacept [Orencia]

Adalimumab [Amgevita]

Adalimumab [Hulio]

Adalimumab [Humira]

Adalimumab [Hyrimoz]

Adalimumab [Imraldi]

Apremilast [Otezla]

Baricitinib [Olumiant]

Brodalumab [Kyntheum]

Certolizumab [Cimzia]

Dimethyl fumarate [Skilarence]

Etanercept [Benepali]

Etanercept [Enbrel]

Etanercept [Erelzi]

Golimumab [Simponi]

Guselkumab [Tremfya]

Infliximab [Flixabi]

Infliximab [Inflectra]

Infliximab [Remicade]
 Infliximab [Remsima]
 Ixekizumab [Taltz]
 Risankizumab [Skyrizi]
 Rituximab [MabThera]
 Rituximab [Rixathon]
 Rituximab [Truxima]
 Sarilumab [Kevzara]
 Secukinumab [Cosentyx]
 Tildrakizumab [Ilumetri]
 Tocilizumab [Ro Actemra]
 Tofacitinib [Xeljanz]
 Upadacitinib [Rinvoq]
 Ustekinumab [Stelara]

RESPONSE

Pharmacy Data Issues between 1st March 2020 to 1st June 2020

NB. Pharmacy dispenses generically and therefore Proprietary names may not be included within the drug description.

The number of patients = Distinct Count for each drug description:

DRUGNAME	Patients
ABATACEPT [:S/C] 125 mg/1ml Pre-filled syringe	24
ABATACEPT 250 mg Infusion	12
ADALIMUMAB "AMGEVITA" 40 mg/0.8ml Pre-filled syringe	267
ADALIMUMAB "HUMIRA" 40 mg/0.4mL Pre-filled syringe	50
APREMILAST 30 mg Tablets	45
APREMILAST INITIATION PACK Tablets	8
BARICITINIB 2 mg Tablets	12
BARICITINIB 4 mg Tablets	39
CERTOLIZUMAB PEGOL 200 mg/1ml Pre-filled syringe	17
DIMETHYL FUMARATE 120 mg Gastro-resistant Tablets	9
DIMETHYL FUMARATE 30 mg Gastro-resistant Tablets	*5 or less
ETANERCEPT [:BENEPALI 25mg] 25 mg/0.5ml Pre-filled syringe	*5 or less

ETANERCEPT [:BENEPALI 50mg] 50 mg/1ml Pre-filled syringe	92
ETANERCEPT [:ENBREL 25mg] 25 mg/0.5ml Pre-filled syringe	27
ETANERCEPT [:ENBREL 50mg] 50 mg Injection	17
GOLIMUMAB 100 mg/1ml Pre-filled disposable device	10
GOLIMUMAB 50 mg/0.5ml Pre-filled disposable device	26
GUSELKUMAB 100 mg Pre-filled disposable device	6
INFLIXIMAB 'REMICADE' 100 mg Injection	*5 or less
INFLIXIMAB 'REMSIMA' [:FKLD1226] 550 mg Infusion	*5 or less
INFLIXIMAB 'REMSIMA' [:FKLD1227] 600 mg Infusion	12
INFLIXIMAB 'REMSIMA' [:FKLD1228] 650 mg Infusion	*5 or less
INFLIXIMAB 'REMSIMA' [FKLD1135] 250 mg Infusion	11
INFLIXIMAB 'REMSIMA' [FKLD1136] 300 mg Infusion	14
INFLIXIMAB 'REMSIMA' [FKLD1137] 350 mg Infusion	21
INFLIXIMAB 'REMSIMA' [FKLD1138] 400 mg Infusion	20
INFLIXIMAB 'REMSIMA' [FKLD1139] 450 mg Infusion	18
INFLIXIMAB 'REMSIMA' [FKLD1140] 500 mg Infusion	8
INFLIXIMAB 'REMSIMA' 100 mg Injection	16
INFLIXIMAB 'REMSIMA' 700 mg Infusion	*5 or less
INFLIXIMAB 'REMSIMA' 750 mg Infusion	*5 or less
INFLIXIMAB 'REMSIMA' in Sodium Chloride 0.9% Infusion	*5 or less
IXEKIZUMAB 80 mg Injection	*5 or less
RITUXIMAB (MABTHERA for SUBCUTANEOUS USE) 1400 mg in 11.7ml Injection	8
RITUXIMAB (TRUXIMA) [:FKLD1105] 600 mg/560ml Infusion	*5 or less
RITUXIMAB (TRUXIMA) [:FKLD1106] 650 mg/565ml Infusion	*5 or less
RITUXIMAB (TRUXIMA) [:FKLD1107] 700 mg/570ml Infusion	13
RITUXIMAB (TRUXIMA) [:FKLD1108] 800 mg/580ml Infusion	10
RITUXIMAB (TRUXIMA) [:FKLD1109] 900 mg/590ml Infusion	*5 or less
RITUXIMAB (TRUXIMA) 100 mg Injection	11
RITUXIMAB (TRUXIMA) 1000 mg/250ml Infusion	10
RITUXIMAB (TRUXIMA) 500 mg Injection	11
SECUKINUMAB 150 mg/1ml Pre-filled disposable device	20
TOCILIZUMAB 162 mg/0.9ml Pre-filled syringe	14
TOCILIZUMAB 200 mg/10mL Injection	18
TOCILIZUMAB 400 mg/20mL Injection	21
TOCILIZUMAB 80 mg/4ml Injection	15
TOFACITINIB 5 mg Tablets	11
USTEKINUMAB 130 mg/26mL Infusion	*5 or less
USTEKINUMAB 45 mg/0.5ml Pre-filled syringe	11
USTEKINUMAB 90 mg/1ml Pre-filled syringe	45

* = **Please note:** We are unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure. In

such circumstances section 40 confers an absolute exemption on disclosure. There is, therefore, no public interest test to apply.